Combating Alzheimer's Through Sleep and Exercise (CASE)

October 23, 2026 updated by: Azizi Seixas, University of Miami

Combating Alzheimer's Through Sleep and Exercise (CASE)

The Combating Alzheimer's through Sleep and Exercise (CASE) study is an exploratory, hypothesis-generating trial designed to: (1) assess whether improvements in sleep are associated with improvements in cognitive performance and cardiovascular and metabolic health; (2) evaluate the effects of structured, moderate-level aerobic and anaerobic exercise on cognitive performance and cardiovascular and metabolic health; (3) examine the combined, potentially synergistic effects of both interventions on cognitive performance and cardiovascular and metabolic health; and (4) investigate the role of light exposure as a potential modulator of sleep parameters.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Florida
      • Miami, Florida, United States, 33136
        • Recruiting
        • University of Miami Hospitals
        • Contact:
        • Principal Investigator:
          • Azizi A Seixas, PhD
        • Sub-Investigator:
          • Alberto Ramos, MD
        • Contact:
        • Sub-Investigator:
          • Debbie Chung, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

55 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Aged 55-80 years at the time of the screening visit
  2. Able to ambulate safely and independently
  3. Able to safely perform moderate-intensity exercise as per the Physical Activity Readiness Questionnaire (PAR-Q, a validated exercise readiness questionnaire)
  4. Able to wear and use Fitbit wristwatch and/or the Elemind Neuromodulation headband and Lys devices
  5. Able to operate a digital device like mobile phone or computer
  6. Able and willing to provide venous blood samples
  7. Able to understand and speak English (our AR-based MCI diagnosis tool does not yet have capacity for other languages)
  8. Able to self-report a history of cognitive changes or impairment
  9. Be cognitively able (including those with and without MCI) and willing to provide informed consent
  10. Body weight <400 pounds (<181.4kg) in order to safely operate the NuStep T4r Recumbent Stepper stationary bicycle

Exclusion Criteria:

  1. Severe mobility limitations that prevent safe participation in moderate exercise protocols
  2. Unstable or uncontrolled medical conditions (e.g., recent cardiovascular event (<6 months), cerebrovascular accident or transient ischemic attack (<6 months), active cancer, or uncontrolled diabetes) that pose safety concerns
  3. Inability to complete intake screening procedures
  4. Severe uncorrected hearing impairment-particularly if it precludes effective utilization of the Elemind Neuromodulation headband-and/or vision impairment that interferes with digital device usage or in-person exercise guidance
  5. Determined to have Alzheimer's/dementia based on performance on the Quick Mild Cognitive Impairment (QMCI).
  6. Inability or unwillingness to learn or engage with digital devices (e.g., smartphone, Fitbit, Elemind, or Lys), even with staff support
  7. Regular pre-study engagement in ≥150 minutes of moderate-level and/or ≥75 minutes of vigorous-level exercise per week based on Fitbit data obtained during the initial seven-day onboarding screening period
  8. Determined to have sufficient sleep, as defined by a sleep efficiency mean of ≥80%) based on Elemind Neuromodulation headband data obtained during the initial seven-day onboarding screening period
  9. Current usage of disease-modifying therapy targeting amyloid (e.g., anti-amyloid monoclonal antibodies) or tau
  10. Body weight ≥400 pounds (≥181.4kg), which would pose a safety risk during the operation of the NuStep recumbent stationary bicycle

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Sleep Only Group

Participants in this group will wear the Elemind headband 3-4 times weekly for 8 weeks.

The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm.

Active Comparator: Exercise Only Group

Participants in this group will participate in a structured, on-site, twice a week exercise program for 60 minutes/session for 8 weeks (16 total sessions). Each exercise session is comprised of 60 minutes, including 10 minutes of warm-up, 20 minutes of cardiovascular exercise on a stationary bike, 20 minutes of resistance training (1 day of upper body focus, 1 day of lower body focus each week), and 10 minutes of cooling off).

Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks.

Active Comparator: Exercise and Sleep Group

Participants in this group will take part in the on-site, structured exercise program twice per week for 8 weeks in additional to wearing the Elemind headband 3-4 times per week for 8 weeks.

The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm.

Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glycated Hemoglobin (HbA1c) Levels
Time Frame: Up to Week 8

Measured from blood sample

Up to Week 8
Total Cholesterol Levels
Time Frame: Up to Week 8

Measured from blood sample

Up to Week 8
Triglycerides Levels
Time Frame: Up to Week 8

Measured from blood sample

Up to Week 8
High-sensitivity C-reactive protein (hs-CRP) Levels
Time Frame: Up to Week 8

Measured from blood sample

Up to Week 8
Low-Density Lipoprotein (LDL) Levels
Time Frame: Up to Week 8

Measured from blood sample

Up to Week 8
C-Peptides
Time Frame: Up to Week 8

Measured from blood sample

Up to Week 8
High-Density Lipoprotein (HDL) Levels
Time Frame: Up to Week 8

Measured from blood sample

Up to Week 8
Cognitive Function
Time Frame: Up to 8 weeks

Cognitive function gauged from Altoida's Digital Neuro-Signatures

Up to 8 weeks
Insulin Levels
Time Frame: Up to 8 weeks

Measured from blood sample

Up to 8 weeks
Neurofilament light chain
Time Frame: Up to Week 8

Measured from blood sample

Up to Week 8

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total Sleep Duration
Time Frame: Up to Week 8

Measured from Elemind

Up to Week 8
Slow Wave Sleep Duration
Time Frame: Up to Week 8

Measured from Elemind

Up to Week 8
%Slow-wave Sleep
Time Frame: Up to Week 8

Measured by Elemind headband

Up to Week 8
Rapid Eye Movement Duration
Time Frame: Up to Week 8

Measured by Elemind headband

Up to Week 8
%REM
Time Frame: Up to Week 8

Measured by Elemind headband

Up to Week 8
Light Non-Rapid Eye Movement Duration
Time Frame: Up to Week 8

Measured by Elemind headband

Up to Week 8
%Light Non-Rapid Eye Movement Sleep
Time Frame: Up to Week 8

Measured by Elemind headband

Up to Week 8
Sleep Efficiency
Time Frame: Up to Week 8

Measured by Elemind headband

Up to Week 8
Sleep Onset Latency
Time Frame: Up to Week 8

Measured by Elemind headband

Up to Week 8
Restlessness (Restless Bouts/Hour during Sleep)
Time Frame: Up to Week 8

Measured by Elemind headband

Up to Week 8

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Light Exposure
Time Frame: Up to Week 8

Measured by LYS Device

Up to Week 8
Psychosocial Metrics
Time Frame: Up to Week 8

Measured by Questionnaires

Up to Week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Azizi A Seixas, PhD, University of Miami

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2023

Primary Completion (Estimated)

December 30, 2028

Study Completion (Estimated)

December 30, 2028

Study Registration Dates

First Submitted

April 19, 2021

First Submitted That Met QC Criteria

April 19, 2021

First Posted (Actual)

April 22, 2021

Study Record Updates

Last Update Posted (Actual)

October 27, 2026

Last Update Submitted That Met QC Criteria

October 23, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 20220931
  • 20-01023 (Other Identifier: NYU)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.